Alexion, AstraZeneca Rare Disease
Alexion, AstraZeneca’s Rare Disease group, was created following the 2021 acquisition of Alexion
Pharmaceuticals, Inc. For more than 30 years, Alexion’s mission has been to transform the lives
of people affected by rare diseases through the development and delivery of innovative
medicines, supportive technologies and healthcare services. Dedicated to continuing its mission
as part of AstraZeneca, Alexion recognizes that patients and caregivers are people first, and by
understanding their experiences, Alexion is better able to serve their unique needs.
Alexion’s pioneering legacy in rare disease is rooted in being the first to translate the complex
biology of the complement system into novel medicines. Alexion pushes boundaries to
accelerate discovery of life-changing medicines. Headquartered in Boston, Massachusetts,
Alexion has offices around the world and continues to expand its reach to benefit more people
globally. For more information, please visit www.alexion.com.
